GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Asset Turnover

Shanghai Junshi Biosciences Co (HKSE:01877) Asset Turnover : 0.03 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Shanghai Junshi Biosciences Co's Revenue for the three months ended in Mar. 2024 was HK$413.7 Mil. Shanghai Junshi Biosciences Co's Total Assets for the quarter that ended in Mar. 2024 was HK$12,745.1 Mil. Therefore, Shanghai Junshi Biosciences Co's Asset Turnover for the quarter that ended in Mar. 2024 was 0.03.

Asset Turnover is linked to ROE % through Du Pont Formula. Shanghai Junshi Biosciences Co's annualized ROE % for the quarter that ended in Mar. 2024 was -16.07%. It is also linked to ROA % through Du Pont Formula. Shanghai Junshi Biosciences Co's annualized ROA % for the quarter that ended in Mar. 2024 was -9.65%.


Shanghai Junshi Biosciences Co Asset Turnover Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Asset Turnover Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial 0.18 0.26 0.43 0.12 0.12

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.04 -0.06 - 0.03

Competitive Comparison of Shanghai Junshi Biosciences Co's Asset Turnover

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Asset Turnover falls into.



Shanghai Junshi Biosciences Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Shanghai Junshi Biosciences Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1643.457/( (14044.124+12428.023)/ 2 )
=1643.457/13236.0735
=0.12

Shanghai Junshi Biosciences Co's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=413.668/( (12428.023+13062.217)/ 2 )
=413.668/12745.12
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Shanghai Junshi Biosciences Co  (HKSE:01877) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Shanghai Junshi Biosciences Co's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-1229.82/7650.9455
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1229.82 / 1654.672)*(1654.672 / 12745.12)*(12745.12/ 7650.9455)
=Net Margin %*Asset Turnover*Equity Multiplier
=-74.32 %*0.1298*1.6658
=ROA %*Equity Multiplier
=-9.65 %*1.6658
=-16.07 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Shanghai Junshi Biosciences Co's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-1229.82/12745.12
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1229.82 / 1654.672)*(1654.672 / 12745.12)
=Net Margin %*Asset Turnover
=-74.32 %*0.1298
=-9.65 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Shanghai Junshi Biosciences Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines